Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 3, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Myelodysplastic Syndrome With Excess Blasts-1Myelodysplastic Syndrome With Excess Blasts-2Myelodysplastic Syndromes

Interventions

DRUG

Fludarabine, Busulfan and Melphalan

Use Fludarabine, Busulfan and Melphalan as myeloablative conditioning regimen for untreated MDS-EB patients.

Trial Locations (1)

RECRUITING

Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER